ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025
Systemic inhibition of soluble TNF significantly changes glial cell populations leading to improved myelin integrity and better functional outcome after experimental stroke.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Skimmianine Pretreatment Attenuates Cerebellar Neuroinflammation and Myelin Injury Following Experimental Cerebral Ischemia-Reperfusion.Antioxidants (Basel, Switzerland) · 2026Article
- Steric hindrance-mediated extracellular vesicle size fractionation for rapid prehospital diagnosis of intracerebral hemorrhage.Nature communications · 2026Article
- Glial-mediated immune modulation in glaucomatous neurodegeneration: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Tumor necrosis factor (TNF) is highly upregulated after ischemic stroke and plays a crucial role in shaping the neuroinflammatory response that follows. Therapies aimed at inhibiting detrimental soluble (sol)TNF-TNF receptor 1 (TNFR1) signaling are gaining interest as new treatment options for neuroinflammatory conditions. We previously demonstrated that XPro1595, a selective solTNF inhibitor, decreased inflammation and improved functional outcome in the acute phase of experimental stroke. Here, we extended these studies by investigating the effects of solTNF inhibition on inflammation, functional outcome, and cognitive impairments in the subacute phases after stroke onset. We observed that in mice treated with XPro1595, glial cell responses were altered 7 and 14 days after experimental stroke, with changes in microglial morphology, as well as astrocyte and oligodendrocyte cell populations, pointing to altered reactive states. While the number of pre-myelinating oligodendrocytes was decreased in the ipsilateral cortex, XPro1595 upregulated oligodendrocyte lipid levels and improved myelin integrity. Similarly, the number of astrocytes in the ipsilateral cortex was decreased with XPro1595 treatment, followed by changes to their lipid profile. Moreover, the treatment led to a decrease in systemic immune cell numbers, indicative of a dampened peripheral inflammatory response. These changes were followed by increased hippocampal pro-brain-derived neurotrophic factor levels and an improvement in cognitive function, seen as better recognition memory, as well as improved motor asymmetry. In conclusion, these findings support a long-term protective effect of inhibiting solTNF in experimental ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.